Evidence map›Paper›PMID 24563618›Full record

ArticleNeoplasia (New York, N.Y.)2014

HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker.

Giuseppe Sconocchia, Serenella Eppenberger-Castori, Inti Zlobec, Eva Karamitopoulou, Roberto Arriga, Andrea Coppola, Sara Caratelli, Giulio Cesare Spagnoli, Davide Lauro, Alessandro Lugli and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neoplasia (New York, N.Y.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 139 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 5 countries.

Giuseppe SconocchiaLaboratory of Tumor Immunology and Immunotherapy, Institute of Translational Pharmacology, Department of Medicine, CNR, Rome, Italy.
Serenella Eppenberger-CastoriInstitute of Pathology, University of Basel, Basel, Switzerland.
Inti ZlobecInstitute of Pathology, University of Bern, Bern, Switzerland.
Eva KaramitopoulouInstitute of Pathology, University of Bern, Bern, Switzerland ; First Department of Pathology, Medical School, University of Athens, Athens, Greece.
Roberto ArrigaDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Andrea CoppolaDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Sara CaratelliLaboratory of Tumor Immunology and Immunotherapy, Institute of Translational Pharmacology, Department of Medicine, CNR, Rome, Italy.
Giulio Cesare SpagnoliInstitute for Surgical Research and Hospital Management, University of Basel, Basel, Switzerland.
Davide LauroDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Alessandro LugliInstitute of Pathology, University of Bern, Bern, Switzerland.
Junyi HanInstitute for Surgical Research and Hospital Management, University of Basel, Basel, Switzerland ; Department of Gastroenterology, Shangai East Hospital, Tongji University, Shangai, PR China.
Giandomenica IezziInstitute for Surgical Research and Hospital Management, University of Basel, Basel, Switzerland.
Cristina FerroneDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Amedeo FerlosioDepartment of Biopathology, University of Rome Tor Vergata, Rome, Italy.
Luigi TornilloInstitute of Pathology, University of Basel, Basel, Switzerland.
Raoul DroeserInstitute for Surgical Research and Hospital Management, University of Basel, Basel, Switzerland.
Piero RossiDepartment of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
Antonio AttanasioDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Soldano FerroneDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Luigi TerraccianoInstitute of Pathology, University of Basel, Basel, Switzerland.
University of Rome Tor Vergata · ITUniversity Hospital of Basel · CHUniversity of Basel · CHUniversity of Bern · CHHarvard University · USIstituto di Farmacologia Traslazionale · ITTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The goal of this study was to determine the frequency of HLA class II antigen expression in colorectal carcinoma (CRC) tumors, its association with the clinical course of the disease, and the underlying mechanism(s). Two tissue microarrays constructed with 220 and 778 CRC tumors were stained with HLA-DR, DQ, and DP antigen-specific monoclonal antibody LGII-612.14, using the immunoperoxidase staining technique. The immunohistochemical staining results were correlated with the clinical course of the disease. The functional role of HLA class II antigens expressed on CRC cells was analyzed by investigating their in vitro interactions with immune cells. HLA class II antigens were expressed in about 25% of the 220 and 21% of the 778 tumors analyzed with an overall frequency of 23%. HLA class II antigens were detected in 19% of colorectal adenomas. Importantly, the percentage of stained cells and the staining intensity were significantly lower than those detected in CRC tumors. However, HLA class II antigen staining was weakly detected only in 5.4% of 37 normal mucosa tissues. HLA class II antigen expression was associated with a favorable clinical course of the disease. In vitro stimulation with interferon gamma (IFNγ) induced HLA class II antigen expression on two of the four CRC cell lines tested. HLA class II antigen expression on CRC cells triggered interleukin-1β (IL-1β) production by resting monocytes. HLA class II antigen expression in CRC tumors is a favorable prognostic marker. This association may reflect stimulation of IL-1β production by monocytes.

Indexed as

Gene Expression Regulation, NeoplasticCarcinomaCell Line, TumorColorectal NeoplasmsDisease ProgressionFemaleGene Expression ProfilingHistocompatibility Antigens Class IIHLA-DP AntigensHLA-DQ AntigensHLA-DR AntigensHumansInflammationInterferon-gammaInterleukin-1betaInterleukin-6Histocompatibility Antigens Class IIHLA-DP AntigensHLA-DQ AntigensHLA-DR AntigensInterferon-gammaInterleukin-1betaInterleukin-6

Identifiers

PMID24563618
PMCPMC3924546
OpenAlexW1842119890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.